Melatonin causes regression of endometriotic implants in rats by modulating angiogenesis, tissue levels of antioxidants and matrix metalloproteinases

Archives of Gynecology and Obstetrics

Volumn 292, Issue 1, 2015, Pages 209-216

  Yilmaz, Bulent ^a,b,e   Kilic, Sevtap ^b   Aksakal, Orhan ^b   Ertas, Ibrahim Egemen ^b   Tanrisever, Gonca Gul ^a   Aksoy, Yasemin ^c   Lortlar, Nese ^d   Kelekci, Sefa ^a   Gungor, Tayfun ^b  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b Zekai Tahir Burak Women's Health Training and Education Hospital   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY   (Turkey)

^e NONE   (Turkey)

Author keywords

MDA; Melatonin; MMP 9; Rat endometriosis; SOD; TIMP 2; VEGF

Indexed keywords

ANTIOXIDANT; GELATINASE B; MALONALDEHYDE; MATRIX METALLOPROTEINASE; MELATONIN; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN A;

ANIMAL; DISEASE MODEL; ENDOMETRIOSIS; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; FEMALE; INJECTIONS, INTRAPERITONEAL; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MELATONIN; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939978536     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3599-4     Document Type: Article

References (49)

1. Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, Reiter RJ (2009) Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 92:328–343
2. Sampson JA (1927) Peritoneal endometriosis is due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 4:433–469
3. Van Langendonckt A, Casanas-Roux F, Donnez J (2002) Oxidative stress and peritoneal endometriosis. Fertil Steril 77:861–870
4. Dizerega GS, Barber DL, Hodgen GD (1980) Endometriosis:role of ovarian steroids in initiation, maintenance and suppression. Fertil Steril 33:649–653
5. Gupta S, Agarwal A, Krajcir N, Alvarez JG (2006) Role of oxidative stress in endometriosis. Reprod Biomed Online 13:126–134
6. Halliwell B, Gutteridge JMC (1999) Free radicals, other reactive species and disease. In: Halliwell B, Gutteridge JMC (eds) Free radicals in biology and medicine, 3rd edn. Oxford University Press, Oxford, pp 639–645
7. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125
8. Chung HW, Lee JY, Moon HS, Hur SE, Park MH, Wen Y, Polan ML (2002) Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril 78:787–795
9. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98:2572–2579
10. Collette T, Bellehumeur C, Kats R, Maheux R, Mailloux J, Villeneuve M, Akoum A (2004) Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod 19:1257–1264
11. Paul S, Sharma AV, Mahapatra PD, Bhattacharya P, Reiter RJ, Swarnakar S (2008) Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis. J Pineal Res 44:439–449
12. Paul S, Bhattacharya P, Das Mahapatra P, Swarnakar S (2010) Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway. J Pineal Res 49:156–168
13. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG (1997) Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nüde mice. J Clin Invest 99:2851–2857
14. Sevket O, Sevket A, Molla T, Sevket O, Sevket A, Molla T, Buyukpınarbasılı N, Uysal O, Yılmaz B, Dane B, Kelekcı S (2013) Somatostatin analogs regress endometriotic implants in rats by decreasing implant levels of vascular endothelial growth factor and matrix metaloproteinase 9. Reprod Sci 20:639–645
15. Ergenoglu AM, Yeniel AO, Erbas O, Aktuğ H, Yildirim N, Ulukuş M, Taskiran D (2013) Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod Sci 20:1230–1236
16. Reiter RJ, Tan DX, Maldonado MD (2005) Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 39:215–216
17. Galano A, Tan DX, Reiter RJ (2013) On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res 54:245–257
18. Güney M, Oral B, Karahan N, Mungan T (2008) Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril 89:934–942
19. Koc O, Gunduz B, Topcuoglu A, Bugdayci G, Yilmaz F, Duran B (2010) Effects of pinealectomy and melatonin supplementation on endometrial explants in a rat model. Eur J Obstet Gynecol Reprod Biol 153:72–76
20. Yildirim G, Attar R, Ozkan F, Kumbak B, Ficicioglu C, Yesildaglar N (2010) The effects of letrozole and melatonin on surgically induced endometriosis in a rat model: a preliminary study. Fertil Steril 93:1787–1792
21. Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44:684–694
22. Lebovic DI, Kir M, Casey CL (2004) Peroxisome proliferator–activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 82:1008–1013
23. Oktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB (2007) High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 22:1474–1480
24. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A (1999) Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72:135–141
25. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
26. Mihara M, Uchiyama M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271–278
27. Yilmaz B, Ozat M, Kilic S, Gungor T, Aksoy Y, Lordlar N, Sut N, Aksakal O (2010) Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online 20:291–299
28. Yilmaz B, Sucak A, Kilic S, Aksakal O, Aksoy Y, Lortlar N, Sut N, Gungor T (2010) Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol 202:368.e1–368.e8
29. Mccarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721
30. Budwit-Novotny DA, Mccarty KS, Cox EB, Vandekerckhove P (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46:5419–5425
31. Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, Raine-Fenning N (2013) The social and psychological impact of endometriosis on women’s lives: a critical narrative review. Hum Reprod Update 19:625–639
32. Rocha AL, Reis FM, Petraglia F (2012) New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs 21:905–919 Review
33. Dogan E, Saygili U, Posaci C (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 82:1115–1120
34. Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P (2007) Ovulation suppression for endometriosis. Cochrane Database Syst Rev 3:CD000155
35. Ercan CM, Kayaalp O, Cengiz M, Keskin U, Yumusak N, Aydogan U, Ide T, Ergun A (2014) Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model. Arch Gynecol Obstet. Nov 4. (Epub ahead of print)
36. Cetinkaya N, Attar R, Yildirim G, Ficicioglu C, Ozkan F, Yilmaz B, Yesildaglar N (2014) The effects of different doses of melatonin treatment on endometrial implants in an oophorectomized rat endometriosis model. Arch Gynecol Obstet. Sep 16. (Epub ahead of print)
37. Simsek Y, Gul M, Yilmaz E, Ozerol IH, Ozerol E, Parlakpinar H (2014) Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model. Arch Gynecol Obstet 290:999–1006
38. Onalan G, Gulumser C, Mulayim B, Dagdeviren A, Zeyneloglu H (2014) Effects of amifostine on endometriosis, comparison with N-acetyl cysteine, and leuprolide as a new treatment alternative: a randomized controlled trial. Arch Gynecol Obstet 289:193–200
39. Azimirad A, Alborzi S, Kumar PV, Zarei A, Azimirad M (2013) The effects of levamisole on experimental endometriosis: a randomized controlled trial in a rat model. Arch Gynecol Obstet 288:1301–1308
40. Simsek Y, Celik O, Karaer A, Gul M, Yılmaz E, Koc O, Colak C, Zengin S, Aydin NE (2013) Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet 286:777–783
41. Hu L, Li LA, Li Y (2012) Preliminary study on the effects of carbon dioxide and nitrogen pneumoperitoneums on endometriotic lesions. Arch Gynecol Obstet 286:389–393
42. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M (2006) The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 132:501–509
43. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, Osteen KG (2002) Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab 87:4782–4791
44. Rudra DS, Pal U, Maiti MC, Reiter RJ, Swarnakar S (2013) Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site. J Pineal Res 54:398–405
45. Schwertner A, Conceição Dos Santos CC, Deitos A, de Souza A, de Souza IC, Torres IL, da Cunha Filho JS, Caumo W (2013) Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial. Pain 154:874–881
46. Alvarez-García V, González A, alonso-González C, Martínez-Campa C, Cos S (2013) Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 54:373–380
47. Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL, González-Gallego J (2013) Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 109:83–91
48. Ganguly K, Sharma AV, Reiter RJ, Swarnakar S (2010) Melatonin promotes angiogenesis during protection and healing of indomethacin-induced gastric ulcer: role of matrix metaloproteinase-2. J Pineal Res 49:130–140
49. Ganguly K, Kundu P, Banerjee A, Reiter RJ, Swarnakar S (2006) Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med 41:911–925